万孚生物：8月19日召开董事会会议

Group 1 - The core point of the article is that Wanfu Biotech announced the convening of its fifth board meeting to discuss the confirmation and increase of related party transactions for the first half of 2025 [2] - In 2024, the revenue composition of Wanfu Biotech is reported to be 97.59% from diagnostic products and 2.41% from other sources [2]